- Home
- RNGT vs XOMA Comparison
RNGT vs XOMA Comparison
Compare RNGT & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RNGT | XOMA |
|---|---|---|
| Founded | 2025 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 313.0M | 308.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RNGT | XOMA |
|---|---|---|
| Price | $10.02 | $38.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $60.60 |
| AVG Volume (30 Days) | 85.0K | ★ 109.9K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $24.59 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $29.64 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.90 | $20.00 |
| 52 Week High | $10.05 | $39.92 |
Technical Indicators
Market Signals| Indicator | RNGT | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 57.47 | 87.42 |
| Support Level | $9.95 | $23.96 |
| Resistance Level | N/A | $39.46 |
| Average True Range (ATR) | 0.02 | 1.68 |
| MACD | 0.00 | 0.70 |
| Stochastic Oscillator | 100.00 | 99.01 |
Price Performance
Historical ComparisonAbout RNGT Range Capital Acquisition Corp II Class A Ordinary Shares
Range Capital Acquisition Corp II is a blank check company.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.